Too many Medical Reps are chasing too few doctors, and thinking that doctors have some deep-rooted memory problem and need to be constantly reminded of brand names, whether in parking lots or hospital corridors. Why would the doctor forget something that’s important to his patient’s wellbeing? MedicinMan in association with…
With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.
The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.
Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”
Smaller Indian pharma companies bore the strongest impact from COVID-19 pandemic – MedicinMan Indian Pharma Digital Adoption Survey Smaller Indian pharma companies with less than a 100 MSRs and less than Rs.100 Cr. turnover were the most highly impacted from the COVID-19 pandemic in the last 12 months. That can…
First Ever India Centric Survey: A CredoWeb – MedicinMan Research Project
We are in the middle of huge crisis and uncertainty. The Covid-19 crisis is taking a toll on Indian Pharma Leaders. Many leaders are not sure – what is of critical importance at this time? What are they are supposed to do and how they are supposed to do it?…
The COVID crisis has impacted IPM negatively – the growth seen in July 2020 was a mere 0.2%. This is down to -2.2% de-growth in August 2020 and shows a single digit growth of 4.1% on a MAT basis. #Cardiac has stabilized but with lower growth of 11.5% in August 2020…
While there is a big buzz around digital adoption by Indian Pharma, necessitated by the disruption brought about by Covid-19, it is also a good time to discuss the future of Indian Pharma market and how it is likely to shape up. This article by Rajeev Kumar was published in…
It is well accepted that pharma field force access to doctors has been decreasing over the years. However, face to face interactions are preferred whenever the doctors think that they add value. The question then becomes one of how to define value. While different doctors will value different things, this…
How should healthcare business leaders (pharma, devices, diagnostics, disposables and other related healthcare service providers to doctors and hospitals) respond to the challenges created by the Covid-19 pandemic? Covid-19 pandemic has created a two-fold challenge for medical doctors and healthcare workers. On one hand, those who are in the forefront…